Published in J Psychopharmacol on January 01, 2008
Deficits in cortical, diencephalic and midbrain gray matter in alcoholism measured by VBM: Effects of co-morbid substance abuse. Neuroimage Clin (2013) 0.90
Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. Neuroimage (2016) 0.75
Decreased subcortical volumes in alcohol dependent individuals: effect of polysubstance use disorder. Addict Biol (2016) 0.75
Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry (2012) 5.45
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2005) 1.88
Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol (2008) 1.80
Role of GABA in anxiety and depression. Depress Anxiety (2007) 1.79
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A (2012) 1.79
Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev (2010) 1.66
The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol (2013) 1.62
Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry (2005) 1.62
GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev (2012) 1.61
Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis (2008) 1.59
A tale of two Es. J Psychopharmacol (2006) 1.53
Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol (2011) 1.47
MDMA, politics and medical research: have we thrown the baby out with the bathwater? J Psychopharmacol (2007) 1.42
Dopamine and social anxiety disorder. Rev Bras Psiquiatr (2006) 1.38
Prescribing antidepressants post Cipriani et al. J Psychopharmacol (2009) 1.37
Human taste thresholds are modulated by serotonin and noradrenaline. J Neurosci (2006) 1.36
Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol (2003) 1.36
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol (2014) 1.36
Effects of the CACNA1C risk allele for bipolar disorder on cerebral gray matter volume in healthy individuals. Am J Psychiatry (2009) 1.35
Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med (2006) 1.25
Sustained attention-deficit confirmed in euthymic bipolar disorder but not in first-degree relatives of bipolar patients or euthymic unipolar depression. Biol Psychiatry (2005) 1.23
Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol (2013) 1.22
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2014) 1.22
Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry (2009) 1.20
Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly. Diabetes Care (2012) 1.16
Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab (2010) 1.16
Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology (2010) 1.16
The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse (2007) 1.15
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res (2003) 1.13
Striatal dopamine D₂/D₃ receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage (2012) 1.13
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Functional connectivity analysis of the neural circuits of opiate craving: "more" rather than "different"? Neuroimage (2003) 1.10
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology (Berl) (2007) 1.10
Cape Town consensus on posttraumatic stress disorder. CNS Spectr (2009) 1.09
Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety (2005) 1.09
Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry (2004) 1.08
Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry (2006) 1.08
Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol (2007) 1.07
Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci (2013) 1.07
Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol (2005) 1.07
WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr (2003) 1.06
Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology (2007) 1.05
Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol (2009) 1.05
Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br J Psychiatry (2008) 1.04
Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol (2005) 1.03
Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol (2013) 1.03
Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull (2012) 1.03
Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.03
The effect of ageing on grey and white matter reductions in schizophrenia. Schizophr Res (2009) 1.02
Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence? Alcohol Alcohol (2005) 1.01
Unique brain areas associated with abstinence control are damaged in multiply detoxified alcoholics. Biol Psychiatry (2011) 1.01
Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol (2013) 1.00
GABAB receptors in addiction and its treatment. Adv Pharmacol (2010) 1.00
Association between the serotonin transporter gene and alcohol consumption in social drinkers. Am J Med Genet B Neuropsychiatr Genet (2005) 1.00
Orexin-A infusion in the locus ceruleus triggers norepinephrine (NE) release and NE-induced long-term potentiation in the dentate gyrus. J Neurosci (2004) 0.99
In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology (2005) 0.99
Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. J Psychopharmacol (2011) 0.98
Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry (2012) 0.98
Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum Psychopharmacol (2013) 0.98
Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol (2009) 0.97
Molecular genetic gene-environment studies using candidate genes in schizophrenia: a systematic review. Schizophr Res (2013) 0.97
GeneaQuilts: a system for exploring large genealogies. IEEE Trans Vis Comput Graph (2010) 0.96
No psychiatry without psychopharmacology. Br J Psychiatry (2011) 0.95
Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab (2002) 0.95
Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse (2011) 0.95
Acute tryptophan depletion. Part I: rationale and methodology. Aust N Z J Psychiatry (2005) 0.95
Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage (2010) 0.94
Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. Schizophr Res (2010) 0.94
Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol (2009) 0.93
Corpus callosum size and shape alterations in individuals with bipolar disorder and their first-degree relatives. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.93
Cytokine levels in euthymic bipolar patients. J Affect Disord (2010) 0.93
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol (2006) 0.93
Foresight brain science, addiction and drugs project. J Psychopharmacol (2005) 0.93
A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology (2013) 0.92
Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol (2013) 0.91
Comparison of ethyl glucuronide in hair with self-reported alcohol consumption. Alcohol Alcohol (2012) 0.91
Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function. J Psychopharmacol (2003) 0.90
Comparison of alterations in c-fos and Egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. Neuropsychopharmacology (2005) 0.90
History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol (2011) 0.90
Gender differences in brain serotonin transporter availability in panic disorder. J Psychopharmacol (2010) 0.89
Brain imaging studies in human addicts. Eur Neuropsychopharmacol (2003) 0.89
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. Eur Addict Res (2015) 0.89
WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr (2003) 0.87
Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry (2004) 0.87
The clinical pharmacology of acamprosate. Br J Clin Pharmacol (2014) 0.86
Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. Brain Res (2009) 0.86
Personalized risk assessment of drug-related harm is associated with health outcomes. PLoS One (2013) 0.85
Nature or nurture? Determining the heritability of human striatal dopamine function: an [18F]-DOPA PET study. Neuropsychopharmacology (2012) 0.85
Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) (2003) 0.85